Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Nuvation Bio Inc.NYSE: NUVB
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $536K rose 50.6% year over year, behind the +104.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +106.0% a year.
Context
- Depreciation & amortization amounted to 2.8% of revenue in FY2025, down 5.9 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +50.6% toward the trailing-twelve-month pace of +104.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.74M USD
- Year-over-year change
- +154.6%
- 4-year CAGR
- +75.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.74M | +154.6% |
| FY2024 | 2024-12-31 | 683K | +207.7% |
| FY2023 | 2023-12-31 | 222K | +11.6% |
| FY2022 | 2022-12-31 | 199K | +8.2% |
| FY2021 | 2021-12-31 | 184K | — |
Depreciation & Amortization vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 depreciation & amortization of $2.15M is the 6th highest of the 11 companies compared; the peer median is $2.88M.
- Its year-over-year change of +104.9% is the highest of 11, against a peer median of -0.7%.
- Depreciation & amortization amounts to 1.3% of revenue for NUVB, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M | -7.6% | -4.5% | 47.4% | |
| LTM Jun 2026 | $19.38M | -0.5% | +50.7% | 6.2% | |
| LTM Mar 2026 | $13.19M | -9.3% | +20.0% | 72.9% | |
| LTM Mar 2026 | $4.63M | +20.3% | +27.0% | 8.9% | |
| LTM Sep 2026 | $3.73M | +10.4% | +5.3% | 3333.9% | |
| LTM Jun 2026 | $2.15M | +104.9% | +106.0% | 1.3% | |
| LTM Mar 2026 | $2.03M | -0.8% | +34.1% | 9.4% | |
| LTM Jun 2026 | $1.92M | +74.2% | +141.5% | — | |
| LTM Sep 2026 | $1.76M | -24.1% | +61.5% | — | |
| LTM Jun 2026 | $536K | +89.4% | — | — | |
| LTM Jun 2026 | $468K | -3.1% | +21.7% | 0.7% | |
| Peer median (excluding NUVB) | $2.88M | -0.7% | +27.0% | 9.4% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.